Although mutations in more than 90 genes are known to cause CMT, the underlying genetic cause of CMT remains unknown in greater than 50% of affected individuals. The discovery of additional genes that harbor CMT2-causing mutations increasingly depends on sharing sequence data on a global level. In this way -by combining data from four continents, including seven countries -we were able to define mutations in ATP1A1, which encodes the alpha1 subunit of the Na Table 1 ). All reported mutations were absent from >240,000 chromosomes in the gnomAD database, highly conserved across species, predicted to be protein damaging, and were conserved across all four different ATP1A paralogs (in the literature also described as ATP1A isoforms) ( Figure 2B , Table S2 ).
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Text
Charcot-Marie-Tooth disease (CMT) is a clinically and genetically heterogeneous group of monogenic causes of peripheral motor and sensory neuropathy, affecting an estimated 1 in 2,500 individuals. 1 Typical clinical features include distal weakness and atrophy, sensory loss, and absence of reflexes; although additional signs may also be present. Mutations in more than 90 genes have been associated with CMT. 2, 3 For the dominant demyelinating forms (CMT1 [MIM: 118220]), the identification of the genetic cause is possible for 90% of affected individuals. 4 For the dominant axonal forms (CMT2 [MIM: 609260]), however, even the most comprehensive sequencing studies fail to identify the genetic cause in ~47-75% of families.
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Most of the ~40 genes carrying CMT and related disease-causing mutations, identified in the past five years, are supported by only a few families and isolated cases, especially for the dominant forms. Thus, the rarity of new disease-gene associations has fostered data sharing and genetic matchmaking efforts. 6, 7 This study showcases the success of truly global data sharing by reporting mutations that cause dominant CMT2 in a gene not previously connected to CMT, supported by seven families, including genome wide significant LOD scores in two largest families.
This study started with a CMT2 family from Czech Republic (Family 1) that had been studied for over 14 years. The family steadily expanded to 18 members, 11 of whom were affected. Whole exome sequencing, using Agilent SureSelect All Exon kit (Agilent, USA) and Figure   1 , Figure 2 , Table 1 ). All reported mutations were absent from >240,000 chromosomes in the gnomAD database, highly conserved across species, predicted to be protein damaging, and were conserved across all four different ATP1A paralogs (in the literature also described as ATP1A isoforms) ( Figure 2B , Table S2 ).
Neurological examination and electromyography were performed in 30 individuals across five of the studied families. ( Table 2 , Table S1 ). We observed distal weakness in the legs and arms with normal proximal strength in virtually all subjects. Vibratory sensation was typically reduced in the legs and also in the hands in some individuals. The age of symptom onset was variable, ranging from childhood to adult, even within the same family. Several (Table 2 ). CMT Neuropathy Scores version 2 (CMTNSv2) ranged from mild 6 to severely affected 25. 8, 9 Many subjects presented with pes cavus foot structure (see Supplemental Note).
A sural nerve biopsy was available from a 33-year-old affected individual (Family 7), who carried the functionally most severe change p.Asp811Ala. As shown in Figure 2D , there was a pronounced loss of large myelinated fibers, groups of regenerating axons, and a number of thinly-myelinated large axons were present. No signs of inflammation were observed.
These findings are indicative of an axonal peripheral neuropathy and in agreement with the electrophysiological findings in this individual. 
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ATP1A1 is highly constrained (intolerant) for missense and loss-of-function (LoF) variations as calculated by the correlation between observed and expected number of variants. 14 Derived from ExAC, the expected number of missense variants for ATP1A1 is 357.8, but the observed number of variants is only 91 (Z-score=6.9) ( Figure 3A , Table S3 ). The number of loss-of-function variants is also low, leading to the maximum constraint metric for probability of LoF intolerance (pLI=1.00) ( Figure 3B ). 14 Other dominant CMT-associated genes are also significantly more constrained than recessive CMT-associated genes ( Figure 3C ).
Interestingly, ATP1A1 has the second highest constraint value of genes associated with CMT, Crystallographic studies have established that ATP1A1 consists of ten transmembrane helices, and three cytoplasmic domains, individually known as the N (nucleotide binding), P (phosphorylation), and A (actuator) domains ( Figure 2C ). 15, 16 We examined these crystal structures to assess the potential structure-function consequences of the seven unique segregating missense changes that we identified in ATP1A1
( Figure 2C ). Remarkably, five substitutions (p.Ile592Thr, p.Ala597Thr, p.Pro600Ala, p.Pro600Thr, and p.Asp601Phe) map to a hot spot within the helical linker region (residues 592 to 608) that couples the N-and P-domains (red linker in Figure 2C ). These changes likely de-couple ATP-hydrolysis (N-domain) from intermediate phosphorylation (P-domain) that is essential for ion selectivity and driving the two major alternating conformations of the pump.
Only one substitution (p.Leu48Arg) maps to the actuator domain, where it could disrupt the concerted movement of the N-, P-, and A-domains during phosphorylation and pumping. The remaining change, p.Asp811Ala, maps to the transmembrane channel core, where it likely disrupts Na + binding and transport through the membrane. From this analysis, we conclude that the helical linker region between the N-and P-domains is a hot spot for mutational defects in the ATP1A1 pump. However, our observation of additional mutations elsewhere in ATP1A1 indicate that pathogenic mutations are not necessarily localized to a specific region of the pump. This latter observation makes intuitive sense given the long-distance allosteric changes that regulate this complex molecular machine. Figure 3D ). This residue falls into a proposed molecular hinge between the N and P domains. To investigate why ATP1A1 mutations cause an axonal neuropathy, we evaluated the protein levels of ATP1A1 in the peripheral nervous system using mouse monoclonal antibodies against ATP1A1 and ATP1A3 ( Figure 3F and Figure S1 ). Immuno-stained cryosections of adult rat spinal cord ( Figure S1 ) show that ATP1A3 is the main ATP1A paralog localized in the central nervous system, a subset of large sensory axons that are known to be proprioceptors, and small myelinated axons of γ-motor neurons. 24 , 25,26 ATP1A1 was the predominant ATP1A paralog present in most the motor and sensory axons of the ventral and dorsal roots. In addition, the large motor neurons of the ventral horn are also ATP1A1-positive. Thus, most peripheral nerve axons and all Schwann cells contain ATP1A1 protein, so that ATP1A1 mutations could cause an axonal neuropathy by affecting the function of ATP1A1 in one or both cell types.
The membrane bound ATP1A1 is present at high levels in α-motoneurons and most sensory neurons. 27 In peripheral nerve, ATP1A1 localizes to axons (internodal axolemma) and and ATP1A3 are expressed predominantly in the central nervous system and mutations have been associated with familial hemiplegic migraine and dystonia and parkinsonism.
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Reduced activity of Na However, as not all tested substitutions showed reduced Na + ,K + -ATPase activity, additional mechanisms, such as trafficking defects may be revealed in future studies. The identified missense mutations in our study span the gene, with a prominent cluster between residue 592 -601. Of interest, the large gnomAD database does not record any missense variant alleles between residues 590 and 638 in over ~240,000 chromosomes.
In our study, ATP1A1 substitutions were associated with a classic axonal to intermediate length-dependent degeneration of motor and sensory peripheral nerves. We predict that as more affected individuals are screened for variants in ATP1A1, the phenotypic spectrum may expand. Given that ATP1A proteins are ubiquitously present at low levels, a combination of central and peripheral phenotypes is conceivable in some families. We fully expect that extra-PNS features will appear in affected individuals, as we have already noted anecdotally in Family 3 with migraine headaches.
Taken together, we show that ATP1A1 is a cause for dominant axonal to intermediate CMT. This conclusion is supported by strong genetic evidence in seven families, structural protein analysis, comparative molecular genetics evidence, in vitro and in vivo functional experiments, and histological studies. These mutations likely act though haploinsufficiency, similar to ATP1A2 and ATP1A3 changes. This CMT pathway offers therapeutic target considerations. The international collaborative nature of this study was enabled by data aggregation and genetic matchmaking capabilities of the GENESIS platform, spanning four continents, and five countries.
7
The supplemental information contains detailed case reports and motor and sensory nerve conduction velocity scores for select families; additional confocal images displaying the reciprocal expression of α1 and α3 in cryosections of adult rat spinal cord; ATP1A1 variant pathogenicity prediction scores; and ATP1 gene family mutational constraint scores. Motor weakness based on MRC scale (0-5): "+" = weakness present, "-" = no weakness detected/no problems. LL Distal weakness assessed by Anterior Tibialis and Gastrocnemius, LL Proximal weakness assessed by Ilio Psoas and Quadriceps; UL Distal weakness assessed by First Dorsal Interosseous, Abductor Pollicis Brevis, and Adductor Digiti Minimi, UL Proximal weakness assessed by Deltoids, Biceps Brachii, and Triceps. Vibration based on Rydell tuning fork with "5" on scale of "8" being considered normal and Cutaneous based on Pinprick sensation: Normal is no decrease compared to the examiner, 'Red' is reduced, and 'abs' is absent up to level indicated. Both motor and sensory evaluations were based on worst score observed of the two limbs. CMTNSv2 scores are separable into <10 (mild), 11-20 (moderate) or >20 (severe) impairment. 
